Medigene Ag Stock Price To Sales
| MDGEFDelisted Stock | USD 2.59 0.00 0.00% |
Medigene AG fundamentals help investors to digest information that contributes to Medigene's financial success or failures. It also enables traders to predict the movement of Medigene Pink Sheet. The fundamental analysis module provides a way to measure Medigene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medigene pink sheet.
Medigene |
Medigene AG Company Price To Sales Analysis
Medigene's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Medigene Price To Sales | 1.86 X |
Most of Medigene's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medigene AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Medigene AG has a Price To Sales of 1.865 times. This is 91.29% lower than that of the Healthcare sector and 98.1% lower than that of the Biotechnology industry. The price to sales for all United States stocks is 83.67% higher than that of the company.
Medigene Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medigene's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Medigene could also be used in its relative valuation, which is a method of valuing Medigene by comparing valuation metrics of similar companies.Medigene is currently under evaluation in price to sales category among its peers.
Medigene Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0887 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 30.5 M | |||
| Shares Outstanding | 24.56 M | |||
| Shares Owned By Insiders | 6.66 % | |||
| Shares Owned By Institutions | 4.62 % | |||
| Price To Earning | 5.26 X | |||
| Price To Book | 0.92 X | |||
| Price To Sales | 1.86 X | |||
| Revenue | 10.46 M | |||
| Gross Profit | 9.1 M | |||
| EBITDA | (6.49 M) | |||
| Net Income | (9.98 M) | |||
| Cash And Equivalents | 39.38 M | |||
| Cash Per Share | 1.60 X | |||
| Total Debt | 3.73 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 6.04 X | |||
| Book Value Per Share | 2.41 X | |||
| Cash Flow From Operations | (10.75 M) | |||
| Earnings Per Share | 0.42 X | |||
| Price To Earnings To Growth | (0.36) X | |||
| Target Price | 18.82 | |||
| Number Of Employees | 61 | |||
| Beta | 0.88 | |||
| Market Capitalization | 56.49 M | |||
| Total Asset | 59.47 M | |||
| Z Score | 9.0 | |||
| Net Asset | 59.47 M |
About Medigene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medigene AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medigene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medigene AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Medigene Pink Sheet
If you are still planning to invest in Medigene AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigene's history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |